Buscar
Congreso SOLACI
HomeESC 2014.Day 1

Day 1

Ver Categoría
Day 1

ODYSSEY LONG TERM: Safety and efficacy of long-term alirocumab

This was a prospective, randomized, controlled study comparing monoclonal antibody alirocumab with placebo in patients with hypercholesterolemia...
solaci -
Ver más
Day 1

LISTEN: Rosuvastatin versus atorvastatin in Japanese diabetic patients

The treatment of hyperlipidemia is useful in primary and secondary prevention of chronic heart disease and stroke,...
solaci -
Ver más
Day 1

COPPS-2: Colchicine for prevention of post-pericardiotomy syndrome and postoperative atrial fibrillation

180 patients with colchicine 0.5 mg twice daily from 48-72 hs. before surgery versus 180 patients to...
solaci -
Ver más
Day 1

ODYSSEY FH I and FH II: Alirocumab in patients with heterozygous familial hypercholesterolemia

The study included patients with a diagnosis of heterozygous familial hypercholesterolemia who were receiving the maximum tolerated...
solaci -
Ver más
Day 1

SIGNIFY: Ivabradine does not reduce events in patients with stable coronary disease

The increase in heart rate in the setting of chronic coronary artery disease is associated with poor...
solaci -
Ver más
Day 1

ODYSSEYCOMBO II: Alirocumab more effective than ezetimibe when statins are insufficient

The aim of the study was to show a reduction in LDL cholesterol with the use of...
solaci -
Ver más
Day 1

SOLID-TIMI 52: Darapladib to reduce new cardiovascular events after myocardial infarction

This study randomized 1: 1 patient who had been hospitalized for acute coronary syndrome within 30 days...
solaci -
Ver más
Day 1

MORE-CRT: Cardiac resynchronization with quadrupole electrode reduces complications

In approximately 10% of patients for resynchronization therapy implantation of ventricular lead is not possible for anatomical...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

Dr. Omar Tupayachi - 0
TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...

Long Term Results of the International Chimney Registry

Dr. Omar Tupayachi - 0
The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

Dr. Omar Tupayachi - 0
The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

Noticias Institucionales

Hemodynamics and Interventional Cardioangiology Hybrid Training Course SOLACI-CACI

solaci - 0
We are now open for registration to the hybrid training course on Hemodynamics and Interventional Cardioangiology for Technicians and Nurses SOLACI-CACI 2025 Find all course...

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad